About Basic salivary proline-rich protein 2
Basic salivary proline-rich protein 2 (PRB2) is a protein
from Homo sapiens identified by UniProt accession
P02812, 416 residues long.
MolForge cross-references it against 0 known binders and
159 disease associations.
Target properties
| Protein name | Basic salivary proline-rich protein 2 |
| UniProt accession | P02812 |
| Gene | PRB2 |
| Organism | Homo sapiens |
| Length | 416 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (159)
Diseases linked to this target (Open Targets).
- subcutaneous adipose tissue measurement · score 0.04
- central nervous system cancer · score 0.03
- human african trypanosomiasis · score 0.03
- psoriasis · score 0.03
- malaria · score 0.02
- alkaline phosphatase measurement · score 0.02
- Systemic lupus erythematosus · score 0.02
- systemic scleroderma · score 0.02
- parkinsonism-dystonia, infantile · score 0.01
- Infantile dystonia-parkinsonism · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P02812-F1 | alphafold | PREDICTED | 46.66 | — |
Amino-acid sequence (416 residues)
MLLILLSVAL LALSSAQNLN EDVSQEESPS LIAGNPQGAP PQGGNKPQGP PSPPGKPQGP PPQGGNQPQG PPPPPGKPQG PPPQGGNKPQ GPPPPGKPQG PPPQGDKSRS PRSPPGKPQG PPPQGGNQPQ GPPPPPGKPQ GPPPQGGNKP QGPPPPGKPQ GPPPQGDNKS RSSRSPPGKP QGPPPQGGNQ PQGPPPPPGK PQGPPPQGGN KPQGPPPPGK PQGPPPQGDN KSQSARSPPG KPQGPPPQGG NQPQGPPPPP GKPQGPPPQG GNKPQGPPPP GKPQGPPPQG GSKSRSSRSP PGKPQGPPPQ GGNQPQGPPP PPGKPQGPPP QGGNKPQGPP PPGKPQGPPP QGGSKSRSAR SPPGKPQGPP QQEGNNPQGP PPPAGGNPQQ PQAPPAGQPQ GPPRPPQGGR PSRPPQ
Explore Basic salivary proline-rich protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets